Bio€quity Europe | 2019
20th Annual Bio€quity Europe
May 20 - 21, 2019 | Barcelona
LOCATION
Barcelona Travel & Hotel Information
Crowne Plaza Barcelona Fira Center
Avenida Rius I Taulet, 1-3
Barcelona, Spain
The 20th Bio€quity Europe : Hot Topics, Hot Spots
Biotech is entering a golden age. The world is seeing a flood of new therapies that have long been the promise of this industry.
Gene Therapies. Stem Cell Treatments. Antisense. siRNA. CAR T.
Is Europe playing its part?
Are they holding their own in inventing the next-generation of therapies and technologies?
And is Europe creating hot beds of innovation to lead the way forward?
For 20 years, Bio€quity Europe has been holding up a mirror to reflect Europe’s progress in the biotech revolution.
Today, even more exciting science and technologies are on the horizon. But the momentum is global. Europe must keep pace to attract the best talent and investment, create jobs and improve public health.
In 2019, Bio€quity Europe gathers European “Hot Topics” companies and their investors to measure their progress and debate the path forward.
For 20 years, Bio€quity Europe has showcased more than 800 leading European companies to thousands of investment and pharma business development professionals. Delegates from 24 nations attended Bio€quity Europe last year in Ghent.
Presenting Company slots running out. Click here to nominate your company.
Return to Conferences List
SCHEDULE
Sunday, May 19, 2019
19:00
to 21:00
Bio€quity Europe Registration Open
Crowne Plaza Barcelona Fira Center - level 0
Welcome Reception
Crowne Plaza Barcelona Fira Center - Terraza Montjuic
Bio€quity Europe Welcome Reception - Hosted By: BioCentury, EBD Group, Kurma Partners and Seroba Life Sciences
Monday, May 20, 2019
07:45
to 18:00
Registration Open
Crowne Plaza Barcelona Fira Center - level 0
09:00
to 09:25
Offical Greetings from the Hosts
Room - Rubí + Zafir (level -1)
09:25
to 09:30
Euronext Opening Bell Ceremony
Room - Rubí + Zafir (level -1)
09:30
to 10:15
Opening Plenary Session
Room - Rubí + Zafir (level -1)
Hot Topics, Hot Spots
Biotech is entering a golden age. Gene therapies. Stem cell treatments. Antisense. siRNA. CAR T. They are today’s “Hot Topics.”
Is Europe playing its part? And is it creating “Hot Spots” of innovation to lead the way forward? And how Europe must keep pace to attract the best talent and investment, create jobs and improve public health?
For its 20th anniversary, Bio€quity Europe begins with “Biotech in Europe: Scaling Innovation," an exclusive report from Insights Partner McKinsey & Co. Based on a survey of industry KOLs, this report will provide food for discussion on such key questions as:
• Are Europe’s biotech hotspots playing their part in global biotech innovation?
• The great European biotech funding evolution: Where next?
• How can CEOs and investors best play their cards in this context?
Session Chair:
• David Flores, President & CEO, BioCentury
Featuring:
• Jorge Santos da Silva, Ph.D., Partner, McKinsey & Co.
• Are Europe’s biotech hotspots playing their part in global biotech innovation?
• The great European biotech funding evolution: Where next?
• How can CEOs and investors best play their cards in this context?
Session Chair:
• David Flores, President & CEO, BioCentury
Featuring:
• Jorge Santos da Silva, Ph.D., Partner, McKinsey & Co.
10:15
to 11:00
European Leaders Respond
Room - Rubí + Zafir (level -1)
Where Can Europe Lead?
A cross-section of entrepreneurs, researchers and investors debate the McKinsey findings and identify where Europe can create global impact in genetic and genomic medicine, novel modalities, next-generation manufacturing and digital healthcare.
Session Chair:
• Simone Fishburn, Ph.D., VP & Executive Editor, BioCentury
Featuring:
• Jeanne Bolger, M.D., VP, Venture Investments, Johnson & Johnson Development Corp.
• Roel Bulthuis, Managing Director, INKEF Capital
• Miriam Frieden, VP, Search & Evaluation, Novo Nordisk A/S
• Antoine Papiernik, Managing Partner & Chairman, Sofinnova Partners
• Jorge Santos da Silva, Ph.D., Partner, McKinsey & Co.
• Jose Terencio, Ph.D., VP Innovation and R+D Coordination, Grifols Innovation and New Technologies
• Erica Whittaker, Ph.D., Head, UCB Ventures
Session Chair:
• Simone Fishburn, Ph.D., VP & Executive Editor, BioCentury
Featuring:
• Jeanne Bolger, M.D., VP, Venture Investments, Johnson & Johnson Development Corp.
• Roel Bulthuis, Managing Director, INKEF Capital
• Miriam Frieden, VP, Search & Evaluation, Novo Nordisk A/S
• Antoine Papiernik, Managing Partner & Chairman, Sofinnova Partners
• Jorge Santos da Silva, Ph.D., Partner, McKinsey & Co.
• Jose Terencio, Ph.D., VP Innovation and R+D Coordination, Grifols Innovation and New Technologies
• Erica Whittaker, Ph.D., Head, UCB Ventures
11:00
to 11:15
Coffee Break and Presentation Room conversion
Crowne Plaza Barcelona Fira Center
11:15
to 12:00
Plenary 3
Room - Rossini 1 & 2
Creating Hot Topic Companies in Europe
Europe has held its own in the race to bring new modalities to the marketplace. Bio€quity’s globally facing VCs now identify where the next wave of leading edge start-ups can be created in Europe, and what they will have to do to attract finance in the global competition for capital.
Session Chair:
• Jan de Kerpel, Ph.D., Managing Director, Kempen & Co.
Featuring:
• Hakan Goker, Ph.D., Executive Investment Director, M Ventures B.V.
• John de Koning, Ph.D., Partner, LSP
• Jose Antonio Mesa, Life Sciences Managing Director, Caixa Capital Risc
• Søren Møller, Ph.D., Partner, Novo Holdings A/S
• Alan O'Connell, Ph.D., Partner, Seroba Life Science
• Jonathan Tobin, Ph.D., Investment Director, Arix Bioscience plc
Session Chair:
• Jan de Kerpel, Ph.D., Managing Director, Kempen & Co.
Featuring:
• Hakan Goker, Ph.D., Executive Investment Director, M Ventures B.V.
• John de Koning, Ph.D., Partner, LSP
• Jose Antonio Mesa, Life Sciences Managing Director, Caixa Capital Risc
• Søren Møller, Ph.D., Partner, Novo Holdings A/S
• Alan O'Connell, Ph.D., Partner, Seroba Life Science
• Jonathan Tobin, Ph.D., Investment Director, Arix Bioscience plc
Plenary 4
Room - Vivaldi 1 & 2
Creating Conditions for Hot Spots in Europe
Creating magnet zones for science, talent and capital requires policy, regulatory, legal and regional leadership. A cross-section of public and private sector stakeholders assess the environment for building and sustaining high-impact zones for the life sciences in Europe.
Session Chair:
• Gary Howes, Life Sciences Specialist, Lawyer, Senior Counsel, McDermott Will & Emery LLP
Featuring:
• Adelaide Cracco, Head of Life Sciences, European Investment Fund (EIF)
• Frank Kalkbrenner, M.D., Managing Director, Boehringer Ingelheim Venture Fund
• Graziano Seghezzi, Managing Partner, Sofinnova Partners
• Paul‐Peter Tak, M.D., Ph.D., President & CEO, Kintai Therapeutics Inc.
• Griet Vanpoucke, Ph.D., Head, New Ventures, VIB
Session Chair:
• Gary Howes, Life Sciences Specialist, Lawyer, Senior Counsel, McDermott Will & Emery LLP
Featuring:
• Adelaide Cracco, Head of Life Sciences, European Investment Fund (EIF)
• Frank Kalkbrenner, M.D., Managing Director, Boehringer Ingelheim Venture Fund
• Graziano Seghezzi, Managing Partner, Sofinnova Partners
• Paul‐Peter Tak, M.D., Ph.D., President & CEO, Kintai Therapeutics Inc.
• Griet Vanpoucke, Ph.D., Head, New Ventures, VIB
12:00
to 13:45
Lunch
Crowne Plaza Barcelona Fira Center
13:30
to 14:45
CEO Workshop 9.0
Room - Rossini 1
C-Suite Management
Great science and technology eventually need great C-Suite leadership. When is it time to elevate or bring in C-Suite competence? How do you determine which C-Suite roles to fill from within and when is it time to go outside? And what characteristics and qualities make someone a C-suiter? BioEquity's 9th CEO Workshop will explore these topics from a CEO, board and investor perspective.
Session Chair:
• Carole Nuechterlein, Head, Roche Venture Fund
Featuring:
• Joël Jean‐Mairet, Ph.D., General Partner, Ysios Capital Partners
• Allan Marchington, Ph.D., Managing Partner, Bridge Valley Ventures
• Edwin Moses, Ph.D., Former CEO, Ablynx N.V.
• Sarah Shackelton, Partner, Marketing and Talent, Abingworth LLP
Session Chair:
• Carole Nuechterlein, Head, Roche Venture Fund
Featuring:
• Joël Jean‐Mairet, Ph.D., General Partner, Ysios Capital Partners
• Allan Marchington, Ph.D., Managing Partner, Bridge Valley Ventures
• Edwin Moses, Ph.D., Former CEO, Ablynx N.V.
• Sarah Shackelton, Partner, Marketing and Talent, Abingworth LLP
13:30
to 13:45
Presenting Company Sessions
Room - Rossini 2
eTheRNA immunotherapies N.V.
Presenting Company Sessions
Room - Vivaldi 2
EpimAb Biotherapeutics Inc.
13:30
to 13:40
Next Wave Sessions
Room - Vivaldi 1
Senti Biosciences Inc.
13:40
to 13:50
Next Wave Sessions
Room - Vivaldi 1
Confo Therapeutics N.V.
13:45
to 14:00
Presenting Company Sessions
Room - Rossini 2
ISA Pharmaceuticals B.V.
Presenting Company Sessions
Room - Vivaldi 2
Ability Pharmaceuticals S.L.
13:50
to 14:00
Next Wave Sessions
Room - Vivaldi 1
Amylon Therapeutics B.V.
14:00
to 14:15
Presenting Company Sessions
Room - Rossini 2
Mission Therapeutics Ltd.
Presenting Company Sessions
Room - Vivaldi 2
Asceneuron S.A.
14:00
to 14:10
Next Wave Sessions
Room - Vivaldi 1
LNC Therapeutics
14:10
to 14:20
Next Wave Sessions
Room - Vivaldi 1
Mimetas B.V.
14:15
to 14:30
Next Wave Sessions
Room - Rossini 2
Lykera Biomed S.A.
Presenting Company Sessions
Room - Vivaldi 2
Allecra Therapeutics S.A.
14:20
to 14:30
Next Wave Sessions
Room - Vivaldi 1
Beactica AB
14:30
to 14:45
Presenting Company Sessions
Room - Rossini 2
Cardior Pharmaceuticals GmbH
Presenting Company Sessions
Room - Vivaldi 2
IGEM Therapeutics Ltd.
14:30
to 14:40
Next Wave Sessions
Room - Vivaldi 1
Depixus S.A.S.
14:40
to 14:50
Next Wave Sessions
Room - Vivaldi 1
Motion Capture Group
14:45
to 15:00
Presenting Company Sessions
Room - Rossini 2
Laboratoris Sanifit S.L.
Presenting Company Sessions
Room - Vivaldi 2
Apeiron Biologics AG
14:50
to 15:00
Next Wave Sessions
Room - Vivaldi 1
Atriva Therapeutics GmbH
15:00
to 16:15
Regional Host Showcase
Room - Rossini 1
Scaling Up Catalonia
The number of international investors in the BioRegion of Catalonia has doubled in just 2 years. Biocat, the Regional Host of Bio€quity Europe, showcases companies that typify the untapped opportunity for investment in one of Europe’s fastest-growing life science hubs.
Session Chair:
• Jordi Naval, CEO, Biocat
Presenting companies:
• Allinky Biopharma S.L.
• Aniling S.L.
• GlyCardial Diagnostics S.L.
• IDP Pharma S.L.
• VCN Biosciences S.L.
• ZeClinics S.L.
Session Chair:
• Jordi Naval, CEO, Biocat
Presenting companies:
• Allinky Biopharma S.L.
• Aniling S.L.
• GlyCardial Diagnostics S.L.
• IDP Pharma S.L.
• VCN Biosciences S.L.
• ZeClinics S.L.
15:00
to 15:15
Presenting Company Sessions
Room - Rossini 2
Topas Therapeutics GmbH
Presenting Company Sessions
Room - Vivaldi 2
Cantargia AB (SSE:CANTA)
15:00
to 15:10
Next Wave Sessions
Room - Vivaldi 1
Macrophage Pharma Ltd.
15:10
to 15:20
Next Wave Sessions
Room - Vivaldi1
Polyneuron Pharmaceuticals AG
15:15
to 15:30
Presenting Company Sessions
Room - Rossini 2
Minoryx Therapeutics S.L.
Presenting Company Sessions
Room - Vivaldi 2
Oryzon Genomics S.A. (Madrid:ORY)
15:20
to 15:30
Next Wave Sessions
Room - Vivaldi 1
AIMM Therapeutics B.V.
15:30
to 15:45
Presenting Company Sessions
Room - Rossini 2
Genkyotex S.A. (Euronext:GKTX)
Presenting Company Sessions
Room - Vivaldi 2
MC2 Therapeutics A/S
15:30
to 15:40
Next Wave Sessions
Room - Vivaldi 1
Secarna Pharmaceuticals GmbH
15:40
to 15:50
Next Wave Sessions
Room - Vivaldi 1
PDC*line Pharma S.A.S.
15:45
to 16:00
Presenting Company Sessions
Room - Rossini 2
Novadip Biosciences S.A.
Presenting Company Sessions
Room - Vivaldi 2
Pharvaris B.V.
15:50
to 16:00
Next Wave Sessions
Room - Vivaldi 1
iOnctura S.A.
16:00
to 16:15
Presenting Company Sessions
Room - Rossini 2
Aelix Therapeutics S.L.
Presenting Company Sessions
Room - Vivaldi 2
Cellestia Biotech AG
16:00
to 16:10
Next Wave Sessions
Room - Vivaldi 1
Rewind Therapeutics
16:10
to 16:20
Next Wave Sessions
Room - Vivaldi 1
AgomAb Therapeutics N.V.
16:15
to 16:30
Presenting Company Sessions
Room - Rossini 2
Vaxxilon AG
Presenting Company Sessions
Room - Vivaldi 2
M2RLABS
16:20
to 16:30
Next Wave Sessions
Room - Vivaldi1
Rejuvenate Biomed N.V.
16:30
to 17:45
China
Room - Rossini 1
An R&D Hot Spot for European Biotechs
China's regulatory reforms and its adoption of ICH standards have paved the way for Western innovators to extend their global R&D strategies to the second-largest pharma market. At the same time, European and Chinese interests are converging on many Hot Topics, including gene and cell therapies, genomics and digital science. This workshop, organized by BioCentury and BayHelix, examines how European biotechs should be thinking about China as a Hot Spot for accelerating global development.
Session Chair:
• Joshua Berlin, Executive Director, New Ventures, BioCentury
Featuring:
• Dominique Doyen, Director, Business Development, 4SC AG
• Simon Cook, Clinical Research Director, Celleron Therapeutics Ltd.
• Da LIU, Managing Director, CR‐CP Life Science Fund
• Todd Yancey, M.D., SVP, Global Medical Affairs & New Market Development, BeiGene Ltd.
• Dan Zhang, M.D., Chairman, Fountain Medical Development Ltd.
Session Chair:
• Joshua Berlin, Executive Director, New Ventures, BioCentury
Featuring:
• Dominique Doyen, Director, Business Development, 4SC AG
• Simon Cook, Clinical Research Director, Celleron Therapeutics Ltd.
• Da LIU, Managing Director, CR‐CP Life Science Fund
• Todd Yancey, M.D., SVP, Global Medical Affairs & New Market Development, BeiGene Ltd.
• Dan Zhang, M.D., Chairman, Fountain Medical Development Ltd.
16:30
to 16:45
Presenting Company Sessions
Room - Rossini 2
Adrenomed AG
16:30
to 16:40
Next Wave Sessions
Room - Vivaldi 1
Curadigm
16:40
to 16:50
Next Wave Sessions
Room - Vivaldi 1
Artios Pharma Ltd.
16:45
to 17:00
Presenting Company Sessions
Room - Rossini 2
HalioDx S.A.S.
16:50
to 17:00
Next Wave Sessions
Room - Vivaldi 1
Complix N.V.
17:00
to 17:15
Presenting Company Sessions
Room - Rossini 2
Synaffix B.V.
17:00
to 17:10
Next Wave Sessions
Room - Vivaldi 1
ImCheck Therapeutics S.A.S.
17:15
to 17:30
Presenting Company Sessions
Room - Rossini 2
Immunic Inc. (NASDAQ:IMUX)
17:30
to 17:45
Presenting Company Sessions
Room - Rossini 2
Alkahest Inc.
18:30
to 19:00
Transportation to Networking Reception and Dinner
19:00
to 22:30
Networking Reception and Dinner
Palau Reial de Pedralbes - Avinguda Diagonal, 686, 08034 Barcelona
Tuesday, May 21, 2019
07:45
to 15:30
Registration Open
Crowne Plaza Barcelona Fira Center
07:45
to 09:00
Light Breakfast
Crowne Plaza Barcelona Fira Center
09:00
to 10:00
Workshop
Room - Rossini 1
Hot Topics; Hot Stocks
Euronext lays out the strategic value of raising capital on the public stock market -- including the ability to accelerate growth, boost a company's profile with stakeholders and provide liquidity for investors wanting buy or sell shares -- and shows how Euronext's TechShare pre-IPO program can help biotech companies take the next step. Including a Q&A session with Euronext executives.
Session Chair:
• Susana de Antonio, Director, Spain Representative, Euronext
Session Chair:
• Susana de Antonio, Director, Spain Representative, Euronext
09:00
to 09:15
Presenting Company Sessions
Room - Vivaldi 2
Achilles Therapeutics Ltd.
09:00
to 09:10
Next Wave Sessions
Room - Vivaldi 1
Storm Therapeutics Ltd.
09:10
to 09:20
Next Wave Sessions
Room - Vivaldi 1
Senolytic Therapeutics Inc.
09:15
to 09:30
Presenting Company Sessions
Room - Vivaldi 2
DCPrime B.V.
09:20
to 09:30
Next Wave Sessions
Room - Vivaldi 1
SNIPR Biome ApS
09:30
to 09:45
Presenting Company Sessions
Room - Vivaldi 2
NBE-Therapeutics AG
09:30
to 09:40
Next Wave Sessions
Room - Vivaldi 1
OxStem Ltd.
09:40
to 09:50
Next Wave Sessions
Room - Vivaldi 1
VarmX B.V.
09:45
to 10:00
Presenting Company Sessions
Room - Vivaldi 2
MiNA Therapeutics Ltd.
09:50
to 10:00
Next Wave Sessions
Room - Vivaldi 1
Aelin Therapeutics N.V.
10:00
to 11:00
Workshop
Room - Rossini 1
Drawing Your Financing Roadmap
Faced with an expanding range of financing options, early stage biotech executives must figure out how to navigate the pathway from seed through venture and public market rounds, while not missing non-dilutive money along the way. This workshop will review the early stage landscape -- such as financing from angels and family offices -- and debate how companies can best prepare for their next money raise.
Session Chair:
• Brian Coleman, Managing Director, Global Head of Financing & Sales, Locust Walk
Featuring:
• Clara Campàs, Ph.D., Partner, Asabys Partners
• Mark Epstein, Managing Partner, MTS Health Partners L.P.
• Arthur Franken, Partner, Gilde Healthcare
• Robert Habib, CEO, MiNA Therapeutics
• Caroline Saï, Operations Manager, Angels Santé & European Coordinator of the EIT Health Investor Network
Session Chair:
• Brian Coleman, Managing Director, Global Head of Financing & Sales, Locust Walk
Featuring:
• Clara Campàs, Ph.D., Partner, Asabys Partners
• Mark Epstein, Managing Partner, MTS Health Partners L.P.
• Arthur Franken, Partner, Gilde Healthcare
• Robert Habib, CEO, MiNA Therapeutics
• Caroline Saï, Operations Manager, Angels Santé & European Coordinator of the EIT Health Investor Network
10:00
to 10:15
Presenting Company Sessions
Room - Vivaldi 2
Promethera Biosciences S.A.
10:00
to 10:10
Next Wave Sessions
Room - Vivaldi 1
Virion Biotherapeutics Ltd.
10:10
to 10:20
Next Wave Sessions
Room - Vivaldi 1
GammaDelta Therapeutics Ltd.
10:15
to 10:30
Next Wave Sessions
Room - Vivaldi 2
BlueHaven Therapeutics
10:20
to 22:30
Next Wave Sessions
Room - Vivaldi 1
Algenex S.L.
10:30
to 10:45
Presenting Company Sessions
Room - Vivaldi 2
Numab Therapeutics AG
10:30
to 10:40
Next Wave Sessions
Room - Vivaldi 1
Calypso Biotech S.A.
10:40
to 10:50
Next Wave Sessions
Room - Vivaldi 1
Scenic Biotech B.V.
10:45
to 11:00
Presenting Company Sessions
Room - Vivaldi 2
Inivata Ltd.
11:00
to 12:00
Workshop
Room - Rossini 1
“Biotech in Europe: Scaling Innovation"
In a Q&A session, McKinsey & Co. partners provide details on the findings of their survey of European life science executives and investors.
Session Chair:
• Jorge Santos da Silva, Ph.D., Partner, McKinsey & Co.
Session Chair:
• Jorge Santos da Silva, Ph.D., Partner, McKinsey & Co.
11:00
to 11:15
Presenting Company Sessions
Room - Vivaldi 2
Xbrane Biopharma AB
11:15
to 11:30
Presenting Company Sessions
Room - Vivaldi 2
Vaximm AG
11:30
to 11:45
Presenting Company Sessions
Room - Vivaldi 2
IDIBELL
12:00
to 14:00
Grab & Go Lunch
Crowne Plaza Barcelona Fira Center
13:15
to 15:15
Pre-Seed Showcase
Room - Rossini 1
Selected Pre-Seed companies present to a diverse panel of Bio€quity Europe "judges," who provide high-level feedback on the entrepreneurs' presentations, business plans and overall strategy.
Session Chair:
• Eric Pierce, Publisher, BioCentury
Judges:
• Karen Bernstein, Ph.D., Co‐founder & Chairman, BioCentury
• Da LIU, Managing Director, CR‐CP Life Science Fund
• Vanessa Malier, Partner, Kurma Partners
• Alicia Irurzun-Lafitte, Partner, UCB Ventures
Presenting companies (Track 1): The companies presenting in this track are working on cancer and antimicrobial resistance
• (13:15) Remab Therapeutics
• (13:30) Ona Therapeutics S.L.
• (13:45) Valis Pharma
• (14:00) Nanoligent S.L.
• (14:15) AngioTheraGnostics
• (14:30) Cebiotix S.L.
• (14:45) Alderaan Biotechnology
Session Chair:
• Eric Pierce, Publisher, BioCentury
Judges:
• Karen Bernstein, Ph.D., Co‐founder & Chairman, BioCentury
• Da LIU, Managing Director, CR‐CP Life Science Fund
• Vanessa Malier, Partner, Kurma Partners
• Alicia Irurzun-Lafitte, Partner, UCB Ventures
Presenting companies (Track 1): The companies presenting in this track are working on cancer and antimicrobial resistance
• (13:15) Remab Therapeutics
• (13:30) Ona Therapeutics S.L.
• (13:45) Valis Pharma
• (14:00) Nanoligent S.L.
• (14:15) AngioTheraGnostics
• (14:30) Cebiotix S.L.
• (14:45) Alderaan Biotechnology
Pre-Seed Showcase
Room - Vivaldi 1
Selected Pre-Seed companies present to a diverse panel of Bio€quity Europe "judges," who provide high-level feedback on the entrepreneurs' presentations, business plans and overall strategy.
Session Chair:
• Bernard V. Fallon, Managing Director, Industry Research & Education, Biotechnology Innovation Organization (BIO)
Judges:
• Peter Dudek, Partner, MRL Ventures Fund (MRLV)
• William Hariri, Director, Alira Health
• Lluís Pareras, M.D., Ph.D., Managing Partner, Invivo Ventures
• Ed Rayner, Investment Director, Arix Bioscience plc
Presenting companies (Track 2): The companies presenting in this track are working on gene therapies, lupus, CNS disorders and vaccines
• (13:15) PurPose Biotherapeutics
• (13:30) ADmit Therapeutics S.L.
• (13:45) Iproteos S.L.
• (14:00) VIB portfolio company
• (14:15) Gate2Brain
• (14:30) Avida Biotech
• (14:45) Biointaxis S.L.
• (15:00) MicrofluidX Ltd.
Session Chair:
• Bernard V. Fallon, Managing Director, Industry Research & Education, Biotechnology Innovation Organization (BIO)
Judges:
• Peter Dudek, Partner, MRL Ventures Fund (MRLV)
• William Hariri, Director, Alira Health
• Lluís Pareras, M.D., Ph.D., Managing Partner, Invivo Ventures
• Ed Rayner, Investment Director, Arix Bioscience plc
Presenting companies (Track 2): The companies presenting in this track are working on gene therapies, lupus, CNS disorders and vaccines
• (13:15) PurPose Biotherapeutics
• (13:30) ADmit Therapeutics S.L.
• (13:45) Iproteos S.L.
• (14:00) VIB portfolio company
• (14:15) Gate2Brain
• (14:30) Avida Biotech
• (14:45) Biointaxis S.L.
• (15:00) MicrofluidX Ltd.
15:00
to 16:00
Closing Reception
Crowne Plaza Barcelona Fira Center
PRESENTERS
Presenting Company slots running out. Please email Eric Pierce to nominate your company.
Bio€quity Europe 2019 will be anchored by more than 80 investor-validated Presenting and Next Wave Companies. The financial community recognizes that the Presenting Companies are independently chosen by BioCentury based on rigorous criteria, including fundraising validation and upcoming milestones informed by the intelligence of the conference's leading sponsors.
SPONSORS
ORGANIZERS
FOUNDING SPONSOR
INSIGHTS PARTNER
GOLD SPONSOR
SILVER SPONSORS
INTERNATIONAL HOST PARTNER
REGIONAL HOST COMMITTEE
REGIONAL HOST PLATINUM SPONSORS
REGIONAL HOST GOLD SPONSORS
SUPPORTING PARTNERS
FACULTY
